ANTIMICROBIAL ACTIVITY OF ANISOCHILUS CARNOSUS (L.F.) WALL AGAINST THE HUMAN GASTRIC PATHOGEN HELICOBACTER PYLORI

  • Vignesh Shetty Department of Microbiology, Enteric Diseases Division, Central Research Lab, Kasturba Medical College, Manipal University, Manipal - 576 104, Karnataka, India
  • Richard Lobo Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India.
  • Nimmy Kumar Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India.
  • Ramachandra Lingadakai Department of Surgery, Kasturba Medical College, Manipal University, Manipal - 576 104, Karnataka, India.
  • Ganesh C Pai Department of Gastroenterology & Hepatology, Kasturba Medical College, Manipal University, Manipal - 576 104, Karnataka, India.
  • Girish Balaraju
  • Mamatha Ballal Department of Microbiology, Enteric Diseases Division, Central Research Lab, Kasturba Medical College, Manipal University, Manipal - 576 104, Karnataka, India

Abstract

 

 Objective: The prevalence of Helicobacter pylori in India is high, and majority leads to severe gastrointestinal infections. Existing treatment regimens for H. pylori infections have increased failure rates and adverse side effects that desire the search for an effective substitute therapy. Anisochilus carnosus (L.f.) wall (Lamiaceae), a herb which grows once in a year at high elevation is used widely in traditional treatment for the complaints of gastric ulcer and skin diseases. The present study was performed to assess the antibacterial activity of A. carnosus (L.f.) wall, against clinical isolates of H. pylori in vitro.

Methods: A. carnosus leaves were collected-dried and extracted with water and ethanol by cold maceration with ethanol by soxhlet method. The minimum inhibitory concentration (MIC) of extracts was made and tested against 32 clinical and 1 reference strains of H. pylori.

Results: A. carnosus (L.f.) wall inhibited the growth of most of the clinical H. pylori strains. The MIC of A. carnosus (L.f.) wall extracted by cold maceration (aqueous and ethanol) and Soxhlet apparatus (ethanol) ranged from 500 to 62.5 μg/ml, and the majority of the clinical H. pylori strains were inhibited at the MIC of 500 μg/ml of aqueous, ethanol, and Soxhlet ethanol extraction were 63.63%, 43.75%, and 71.87%, respectively.

Conclusion: A. carnosus (L.f.) wall is an efficient inhibitor of H. pylori growth in vitro. A. carnosus (L.f.) wall revealed enormous therapeutic potential to H. pylori infection as it was extremely active in the suppression of H. pylori. Hence, it can be taken as a potential agent against several H. pylori linked gastric pathogenic progressions.

Keywords: Anisochilus carnosus, Helicobacter pylori, Minimum inhibitory concentration, Antimicrobial activity.

References

1. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. Science 1999;284(5418):1328-33.
2. Shetty V, Ballal M, Lingadakai R, Mukhopadhyay AK. Determination of Helicobacter pylori virulence genes in clinical isolates of symptomatic patients from South Coastal region of Karnataka - A preliminary work. Austin J Gastroenterol 2015;2(1):1031.
3. Correa P, Piazuelo MB. Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev 2011;7(1):59-64.
4. Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol 2010;7(11):629-41.
5. Sgouros SN, Bergele C. Clinical outcome of patients with Helicobacter pylori infection: The bug, the host, or the environment? Postgrad Med J 2006;82(967):338-42.
6. Roesler BM, Rabelo-Gonçalves EM, Zeitune JM. Virulence factors of Helicobacter pylori: A review. Clin Med Insights Gastroenterol 2014;7:9-17.
7. Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG, Ferri A, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14(12):1639-43.
8. Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: A paradigm shift to improved efficacy. Gastroenterol Res Pract 2012;2012:757926.
9. Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J Methodol 2015;5(3):164-74.
10. Ashwini P, Sumana MN, Shilpa U, Mamatha P, Manasa P, Dhananjaya BL, et al. A review on Helicobacter pylori: Its biology, complications and management. Int J Pharm Pharm Sci 2015;7 Suppl 1:14-20.
11. Lobo R, Bhagat J, Ballal M, Gupta N. Histo-anatomical study of Anisochilus carnosus (Lf) wall: An Indian habitant. Res J Med Plant 2012;6(6):456-60.
12. Bhagat J, Lobo R, Kumar N, Mathew JE, Pai A. Cytotoxic potential of Anisochilus carnosus (L.f.) Wall and estimation of luteolin content by HPLC. BMC Complement Altern Med 2014 28;14:421.
13. Senatore F, Lentini F, Venza F, Bruno M, Napolitano F. Composition and antibacterial activity of the essential oil of Anisochilus carnosus (Linn. fil.) Benth., a Tamil plant acclimatized in Sicily. Flavour Fragr J 2003;18(3):202-4.
14. Vaira D, Zullo A, Hassan C, Fiorini G, Vakil N. Sequential therapy for Helicobacter pylori eradication: The time is now! Therap Adv Gastroenterol 2009;2(6):317-22.
15. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. Helicobacter pylori eradication with either seven-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol 2006;20(2):113-7.
16. Olokoba AB, Obateru OA, Bojuwoye MO. Helicobacter pylori eradication therapy: A review of current trends. Niger Med J 2013;54(1):1-4.
17. Pandey MM, Rastogi S, Rawat AK. Indian traditional ayurvedic system of medicine and nutritional supplementation. Evid Based Complement Alternat Med 2013;2013:376327.
18. Raj T, Kumar P, Rathee R, Dubey KK. Screening of some medicinal plants for their antimicrobial activities. Int J Pharm Pharm Sci 2016;8(5):202-6. 19. Devi SM, Ahmed I, Francalacci P, Hussain MA, Akhter Y, Alvi A, et al. Ancestral European roots of Helicobacter pylori in India. BMC Genomics 2007;8(1):184.
20. Thirumurthi S, Graham DY. Helicobacter pylori infection in India from a Western perspective. Indian J Med Res 2012;136(4):549-62.
21. Syed A, Vijaya PP, Saranya RS, Yogananth N, Anurath A, Parveen PK. Antimicrobial activity and characterization of biosynthesized silver nanoparticles from Anisochilus carnosus. Int J Nano Dimens 2013;4:255-62.
22. Mohammed A, Kumar RJ, Santosh HY, Nagashruthi MH. Antiulcer activity of Anisochilus carnosus leaf extracts in pylorus ligation rats. Indian Drugs 2008;45(12):979-81.
23. Yadav R, Yadav AK, Mishra PK, Goswami S, Rao CV. Hepatoprotective and antioxidant activity of ethanolic extract of Anisochilus carnosus whole plant against paracetamol induced liver injury. J Chem Pharm Res 2016;8(8):1176-81.
24. Porika V, Dinakar A, Senthilkumar N. Evaluation of hepatoprotective, analgesic and antipyretic activity of aqueous extracts of Boerhavia diffusa and Anisochlilus carnosus. Int J Pharm Bio Sci 2013;4(1):596-603.
Statistics
228 Views | 263 Downloads
Citatons
How to Cite
Shetty, V., R. Lobo, N. Kumar, R. Lingadakai, G. C Pai, G. Balaraju, and M. Ballal. “ANTIMICROBIAL ACTIVITY OF ANISOCHILUS CARNOSUS (L.F.) WALL AGAINST THE HUMAN GASTRIC PATHOGEN HELICOBACTER PYLORI”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 10, Sept. 2017, pp. 292-5, doi:10.22159/ajpcr.2017.v10i10.20304.
Section
Original Article(s)